196 related articles for article (PubMed ID: 20573372)
1. Mesothelin (MSLN) promoter is hypomethylated in malignant mesothelioma, but its expression is not associated with methylation status of the promoter.
Tan K; Kajino K; Momose S; Masaoka A; Sasahara K; Shiomi K; Izumi H; Abe M; Ohtsuji N; Wang T; Hino O; Fujii H
Hum Pathol; 2010 Sep; 41(9):1330-8. PubMed ID: 20573372
[TBL] [Abstract][Full Text] [Related]
2. Value of mesothelin immunostaining in the diagnosis of mesothelioma.
Ordóñez NG
Mod Pathol; 2003 Mar; 16(3):192-7. PubMed ID: 12640097
[TBL] [Abstract][Full Text] [Related]
3. Possible reversibility between epithelioid and sarcomatoid types of mesothelioma is independent of ERC/mesothelin expression.
Kojima M; Kajino K; Momose S; Wali N; Hlaing MT; Han B; Yue L; Abe M; Fujii T; Ikeda K; Hino O
Respir Res; 2020 Jul; 21(1):187. PubMed ID: 32677949
[TBL] [Abstract][Full Text] [Related]
4. Aberrant splicing and protease involvement in mesothelin release from epithelioid mesothelioma cells.
Sapede C; Gauvrit A; Barbieux I; Padieu M; Cellerin L; Sagan C; Scherpereel A; Dabouis G; Grégoire M
Cancer Sci; 2008 Mar; 99(3):590-4. PubMed ID: 18167128
[TBL] [Abstract][Full Text] [Related]
5. The relationship between tumor MSLN methylation and serum mesothelin (SMRP) in mesothelioma.
Nelson HH; Almquist LM; LaRocca JL; Plaza SL; Lambert-Messerlian GM; Sugarbaker DJ; Bueno R; Godleski JJ; Marsit CJ; Christensen BC; Kelsey KT
Epigenetics; 2011 Aug; 6(8):1029-34. PubMed ID: 21775819
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive immunohistochemical study of mesothelin (MSLN) using different monoclonal antibodies 5B2 and MN-1 in 1562 tumors with evaluation of its prognostic value in malignant pleural mesothelioma.
Inaguma S; Wang Z; Lasota J; Onda M; Czapiewski P; Langfort R; Rys J; Szpor J; Waloszczyk P; Okoń K; Biernat W; Ikeda H; Schrump DS; Hassan R; Pastan I; Miettinen M
Oncotarget; 2017 Apr; 8(16):26744-26754. PubMed ID: 28460459
[TBL] [Abstract][Full Text] [Related]
7. Mesothelin gene expression and promoter methylation/hypomethylation in gynecological tumors.
Obulhasim G; Fujii H; Matsumoto T; Yasen M; Abe M; Matsuoka S; Ohtsuji N; Hino O
Eur J Gynaecol Oncol; 2010; 31(1):63-71. PubMed ID: 20349783
[TBL] [Abstract][Full Text] [Related]
8. L1CAM, INP10, P-cadherin, tPA and ITGB4 over-expression in malignant pleural mesotheliomas revealed by combined use of cDNA and tissue microarray.
Kettunen E; Nicholson AG; Nagy B; Wikman H; Seppänen JK; Stjernvall T; Ollikainen T; Kinnula V; Nordling S; Hollmén J; Anttila S; Knuutila S
Carcinogenesis; 2005 Jan; 26(1):17-25. PubMed ID: 15447976
[TBL] [Abstract][Full Text] [Related]
9. MSLN gene silencing has an anti-malignant effect on cell lines overexpressing mesothelin deriving from malignant pleural mesothelioma.
Melaiu O; Stebbing J; Lombardo Y; Bracci E; Uehara N; Bonotti A; Cristaudo A; Foddis R; Mutti L; Barale R; Gemignani F; Giamas G; Landi S
PLoS One; 2014; 9(1):e85935. PubMed ID: 24465798
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic profiles distinguish malignant pleural mesothelioma from lung adenocarcinoma.
Goto Y; Shinjo K; Kondo Y; Shen L; Toyota M; Suzuki H; Gao W; An B; Fujii M; Murakami H; Osada H; Taniguchi T; Usami N; Kondo M; Hasegawa Y; Shimokata K; Matsuo K; Hida T; Fujimoto N; Kishimoto T; Issa JP; Sekido Y
Cancer Res; 2009 Dec; 69(23):9073-82. PubMed ID: 19887624
[TBL] [Abstract][Full Text] [Related]
11. Mesothelin overexpression promotes mesothelioma cell invasion and MMP-9 secretion in an orthotopic mouse model and in epithelioid pleural mesothelioma patients.
Servais EL; Colovos C; Rodriguez L; Bograd AJ; Nitadori J; Sima C; Rusch VW; Sadelain M; Adusumilli PS
Clin Cancer Res; 2012 May; 18(9):2478-89. PubMed ID: 22371455
[TBL] [Abstract][Full Text] [Related]
12. Mesothelin promotes epithelial-to-mesenchymal transition and tumorigenicity of human lung cancer and mesothelioma cells.
He X; Wang L; Riedel H; Wang K; Yang Y; Dinu CZ; Rojanasakul Y
Mol Cancer; 2017 Mar; 16(1):63. PubMed ID: 28288645
[TBL] [Abstract][Full Text] [Related]
13. The use of the monoclonal antibody mesothelin in the diagnosis of malignant mesothelioma in pleural biopsies.
Galloway ML; Murray D; Moffat DF
Histopathology; 2006 May; 48(6):767-9. PubMed ID: 16681698
[No Abstract] [Full Text] [Related]
14. Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case-control study.
Roe OD; Creaney J; Lundgren S; Larsson E; Sandeck H; Boffetta P; Nilsen TI; Robinson B; Kjaerheim K
Lung Cancer; 2008 Aug; 61(2):235-43. PubMed ID: 18281122
[TBL] [Abstract][Full Text] [Related]
15. DNA methylation markers of surfactant proteins in lung cancer.
Lin Z; Thomas NJ; Bibikova M; Seifart C; Wang Y; Guo X; Wang G; Vollmer E; Goldmann T; Garcia EW; Zhou L; Fan JB; Floros J
Int J Oncol; 2007 Jul; 31(1):181-91. PubMed ID: 17549420
[TBL] [Abstract][Full Text] [Related]
16. Establishment of three novel human malignant pleural mesothelioma cell lines: morphological and cytogenetical studies and EGFR mutation status.
Kobayashi M; Takeuchi T; Ohtsuki Y
Anticancer Res; 2008; 28(1A):197-208. PubMed ID: 18383846
[TBL] [Abstract][Full Text] [Related]
17. Utility of WT-1, p63, MOC31, mesothelin, and cytokeratin (K903 and CK5/6) immunostains in differentiating adenocarcinoma, squamous cell carcinoma, and malignant mesothelioma in effusions.
Pu RT; Pang Y; Michael CW
Diagn Cytopathol; 2008 Jan; 36(1):20-5. PubMed ID: 18064689
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical marker panels for distinguishing between epithelioid mesothelioma and lung adenocarcinoma.
Kushitani K; Takeshima Y; Amatya VJ; Furonaka O; Sakatani A; Inai K
Pathol Int; 2007 Apr; 57(4):190-9. PubMed ID: 17316414
[TBL] [Abstract][Full Text] [Related]
19. Claudin 3, 4, and 15 expression in solid tumors of lung adenocarcinoma versus malignant pleural mesothelioma.
Chaouche-Mazouni S; Scherpereel A; Zaamoum R; Mihalache A; Amir ZC; Lebaïli N; Delaire B; Gosset P
Ann Diagn Pathol; 2015 Aug; 19(4):193-7. PubMed ID: 25935651
[TBL] [Abstract][Full Text] [Related]
20. Aberrant methylation of p57KIP2 gene in lung and breast cancers and malignant mesotheliomas.
Kobatake T; Yano M; Toyooka S; Tsukuda K; Dote H; Kikuchi T; Toyota M; Ouchida M; Aoe M; Date H; Pass HI; Doihara H; Shimizu N
Oncol Rep; 2004 Nov; 12(5):1087-92. PubMed ID: 15492797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
